Lixisenatide CAS NO.320367-13-3/827033-10-3

Lixisenatide is a short-acting GLP-1 receptor agonist (GLP-1RA) developed for the treatment of adults with type 2 diabetes. Marketed under brand names such as Adlyxin and as a component of the fixed-ratio combination product Soliqua (in combination with insulin glargine), it is administered as a once-daily subcutaneous injection, typically before the first meal of the day. The product is designed to significantly improve glycemic control, with a pronounced effect on lowering postprandial blood glucose, and offers the added benefit of modest weight reduction. It is indicated for use as an adjunct to diet and exercise, either as monotherapy or in combination with other glucose-lowering agents like metformin, sulfonylureas, or basal insulin when these alone are insufficient.

info@huanqiukeji9.com

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Lixisenatide
CAS NO.	320367-13-3/827033-10-3
Appearance	White to off-white lyophilized powder
Molecular Formula	C215H347N61O65S
Molecular Weight	4858.49 g/mol
Purity (RP-HPLC)	≥ 98.0%
Solubility	Soluble in water and dilute acidic buffers; insoluble in nonpolar organic solvents
Endotoxin	< 0.01 EU/μg
Biological Activity	GLP-1 receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon release
Storage Conditions	Store at 2–8°C protected from light; lyophilized form stable at room temperature if properly sealed
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

Lixisenatide mimics the action of the natural incretin hormone GLP-1 by binding to and activating GLP-1 receptors. Its mechanism is characterized by a glucose-dependent stimulation of insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, and a significant delay in gastric emptying. The slower gastric emptying rate is a key differentiator, as it prolongs nutrient absorption and effectively blunts sharp post-meal blood sugar spikes. Additionally, by acting on central nervous system receptors, it promotes satiety, which contributes to reduced food intake. Unlike long-acting GLP-1 RAs, lixisenatide's pharmacokinetic profile is optimized for short-term, meal-related activity, providing targeted control over postprandial hyperglycemia.

upload/attachment/image/202604/21/17767418761bc90cca902517328f0c61a3ee501575_local.png

2.PRODUCT INDICATIONS

Lixisenatide is indicated to improve glycemic control in adults with type 2 diabetes mellitus, specifically targeting patients whose blood sugar remains uncontrolled despite lifestyle modifications (diet and exercise) and existing oral antidiabetic therapy. It is suitable for a broad patient population, including those on metformin, sulfonylureas, thiazolidinediones, or basal insulin regimens. The product is particularly beneficial for individuals struggling with high postprandial glucose levels, as its pharmacodynamic profile is tailored to manage meal-induced hyperglycemia. It is not indicated for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, and its use in patients with severe gastrointestinal disease, such as gastroparesis, is contraindicated due to its slowing effect on gastric emptying.

upload/attachment/image/202604/21/17767418847daa5d725145aa7e561fd3dee7069949_local.png

3.CLINICAL EFFICACY OF PRODUCT

Clinical efficacy data from the extensive GetGoal phase III trial program demonstrates that Lixisenatide consistently reduces HbA1c levels, with a particularly strong effect on lowering 2-hour postprandial glucose (PPG) excursions. When used as an add-on therapy to basal insulin or oral agents, it provides an additional HbA1c reduction of approximately 0.4–0.9%, while significantly flattening the PPG curve. The product also demonstrates a favorable safety profile with a low risk of hypoglycemia when used without sulfonylureas, and it offers the ancillary benefit of mild to moderate weight loss (typically 1–3 kg). The most common adverse reactions are transient gastrointestinal events, such as nausea and vomiting, which generally diminish over time with continued use.

4.Certificate

GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.

Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.

We prioritize:

1.A rigorous quality management system

2.Batch traceability and stability data

3.Professional laboratory testing and validation

4.Compliance with international trade standards

Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.

upload/attachment/image/202603/11/17731937213fbed5ed3f3869d1613bb629f6365f21_local.png

5.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.

We can also customize packaging according to customer needs.

Shipping Methods

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

upload/attachment/image/202601/20/1768872924be74a0641f7ddbf20e541c97f2066c5c_local.jpg

Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.

We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.

HotTags:Lixisenatide, Adlyxin, GLP1, Type2Diabetes, DiabetesTreatment, PostprandialGlucose, GLP1RA, Soliqua, InsulinTherapy, BloodSugarControl, Supplier, Manufacturer, Bulk order, Pharmaceutical.

If you have any product requirements, please send an email to:info@huanqiukeji9.com;whatsapp:85246842553